
Jae W. Lee
Examiner (ID: 7721, Phone: (571)272-9949 , Office: P/1656 )
| Most Active Art Unit | 1656 |
| Art Unit(s) | 1656 |
| Total Applications | 1186 |
| Issued Applications | 830 |
| Pending Applications | 111 |
| Abandoned Applications | 269 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17385942
[patent_doc_number] => 20220033794
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-03
[patent_title] => ACTIVE LOW MOLECULAR WEIGHT VARIANTS OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2)
[patent_app_type] => utility
[patent_app_number] => 17/391680
[patent_app_country] => US
[patent_app_date] => 2021-08-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23504
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17391680
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/391680 | Active low molecular weight variants of angiotensin converting enzyme 2 (ACE2) | Aug 1, 2021 | Issued |
Array
(
[id] => 17370332
[patent_doc_number] => 20220025384
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-27
[patent_title] => PHYTASE MUTANTS
[patent_app_type] => utility
[patent_app_number] => 17/387909
[patent_app_country] => US
[patent_app_date] => 2021-07-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6382
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 105
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17387909
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/387909 | Phytase mutants | Jul 27, 2021 | Issued |
Array
(
[id] => 17228914
[patent_doc_number] => 20210355470
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-18
[patent_title] => ALPHA-AMYLASE VARIANTS
[patent_app_type] => utility
[patent_app_number] => 17/378288
[patent_app_country] => US
[patent_app_date] => 2021-07-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21790
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17378288
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/378288 | Alpha-amylase variants | Jul 15, 2021 | Issued |
Array
(
[id] => 18559960
[patent_doc_number] => 11725196
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-08-15
[patent_title] => FCE mRNA capping enzyme compositions, methods and kits
[patent_app_type] => utility
[patent_app_number] => 17/377797
[patent_app_country] => US
[patent_app_date] => 2021-07-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 11399
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17377797
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/377797 | FCE mRNA capping enzyme compositions, methods and kits | Jul 15, 2021 | Issued |
Array
(
[id] => 18649414
[patent_doc_number] => 20230295223
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => IMMUNOGLOBULIN BINDING PROTEINS FOR AFFINITY PURIFICATION
[patent_app_type] => utility
[patent_app_number] => 18/016440
[patent_app_country] => US
[patent_app_date] => 2021-07-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15332
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18016440
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/016440 | Immunoglobulin binding proteins for affinity purification | Jul 13, 2021 | Issued |
Array
(
[id] => 17336365
[patent_doc_number] => 20220002696
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-06
[patent_title] => VARIANT MALTOHEXAOSE-FORMING ALPHA-AMYLASE VARIANTS
[patent_app_type] => utility
[patent_app_number] => 17/373307
[patent_app_country] => US
[patent_app_date] => 2021-07-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51392
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 261
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17373307
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/373307 | Variant maltohexaose-forming alpha-amylase variants | Jul 11, 2021 | Issued |
Array
(
[id] => 17228918
[patent_doc_number] => 20210355474
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-18
[patent_title] => MODIFIED MEMBRANE TYPE SERINE PROTEASE 1 (MTSP-1) POLYPEPTIDES AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/371980
[patent_app_country] => US
[patent_app_date] => 2021-07-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 76234
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -54
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17371980
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/371980 | Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use | Jul 8, 2021 | Issued |
Array
(
[id] => 18596096
[patent_doc_number] => 20230270887
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => ACTIVE DELIVERY OF NUCLEIC ACIDS AND PEPTIDES, METHODS AND USES
[patent_app_type] => utility
[patent_app_number] => 18/004126
[patent_app_country] => US
[patent_app_date] => 2021-07-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34594
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 92
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18004126
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/004126 | ACTIVE DELIVERY OF NUCLEIC ACIDS AND PEPTIDES, METHODS AND USES | Jun 30, 2021 | Pending |
Array
(
[id] => 17561747
[patent_doc_number] => 20220125896
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-28
[patent_title] => COMPOSITIONS AND METHODS FOR TREATMENT OF HOMOCYSTINURIA
[patent_app_type] => utility
[patent_app_number] => 17/362633
[patent_app_country] => US
[patent_app_date] => 2021-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37408
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17362633
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/362633 | Compositions and methods for treatment of homocystinuria | Jun 28, 2021 | Issued |
Array
(
[id] => 19339468
[patent_doc_number] => 12049649
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-30
[patent_title] => Ketoreductase polypeptides for the production of azetidinone
[patent_app_type] => utility
[patent_app_number] => 17/357673
[patent_app_country] => US
[patent_app_date] => 2021-06-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 44804
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17357673
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/357673 | Ketoreductase polypeptides for the production of azetidinone | Jun 23, 2021 | Issued |
Array
(
[id] => 18706661
[patent_doc_number] => 20230329233
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-19
[patent_title] => PRO-MICROBIAL SURFACE
[patent_app_type] => utility
[patent_app_number] => 18/011785
[patent_app_country] => US
[patent_app_date] => 2021-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4171
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 78
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18011785
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/011785 | Pro-microbial surface | Jun 22, 2021 | Issued |
Array
(
[id] => 18510051
[patent_doc_number] => 20230226149
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-20
[patent_title] => MODIFIED CAVEOLIN-1 PEPTIDES FOR THE TREATMENT OF PATHOGEN-INDUCED LUNG INJURY
[patent_app_type] => utility
[patent_app_number] => 18/002420
[patent_app_country] => US
[patent_app_date] => 2021-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25326
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -59
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18002420
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/002420 | MODIFIED CAVEOLIN-1 PEPTIDES FOR THE TREATMENT OF PATHOGEN-INDUCED LUNG INJURY | Jun 16, 2021 | Pending |
Array
(
[id] => 18964431
[patent_doc_number] => 11898183
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-13
[patent_title] => Programmed microorganisms to attenuate a disease
[patent_app_type] => utility
[patent_app_number] => 17/344265
[patent_app_country] => US
[patent_app_date] => 2021-06-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 4
[patent_no_of_words] => 13941
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17344265
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/344265 | Programmed microorganisms to attenuate a disease | Jun 9, 2021 | Issued |
Array
(
[id] => 17156381
[patent_doc_number] => 20210317432
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-14
[patent_title] => GLUCOSE ISOMERASE
[patent_app_type] => utility
[patent_app_number] => 17/303882
[patent_app_country] => US
[patent_app_date] => 2021-06-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 94059
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17303882
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/303882 | Glucose isomerase | Jun 8, 2021 | Issued |
Array
(
[id] => 17357131
[patent_doc_number] => 20220017927
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-20
[patent_title] => SYSTEMS AND METHODS FOR ONE-SHOT GUIDE RNA (ogRNA) TARGETING OF ENDOGENOUS AND SOURCE DNA
[patent_app_type] => utility
[patent_app_number] => 17/332764
[patent_app_country] => US
[patent_app_date] => 2021-05-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21788
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17332764
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/332764 | Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA | May 26, 2021 | Issued |
Array
(
[id] => 18485217
[patent_doc_number] => 20230212548
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-06
[patent_title] => SUBTILASE VARIANTS AND COMPOSITIONS COMPRISING SAME
[patent_app_type] => utility
[patent_app_number] => 17/927164
[patent_app_country] => US
[patent_app_date] => 2021-05-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13740
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17927164
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/927164 | SUBTILASE VARIANTS AND COMPOSITIONS COMPRISING SAME | May 25, 2021 | Pending |
Array
(
[id] => 17095333
[patent_doc_number] => 20210283124
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-16
[patent_title] => Cell-Based Screening and Compounds that Modulate GalNAc-Transferases
[patent_app_type] => utility
[patent_app_number] => 17/330779
[patent_app_country] => US
[patent_app_date] => 2021-05-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13467
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17330779
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/330779 | Cell-based screening and compounds that modulate GalNAc-transferases | May 25, 2021 | Issued |
Array
(
[id] => 20788612
[patent_doc_number] => 12662517
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-06-23
[patent_title] => Methods and compositions to spread protein cargoes across multi-nucleated cells
[patent_app_type] => utility
[patent_app_number] => 17/927337
[patent_app_country] => US
[patent_app_date] => 2021-05-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 55
[patent_no_of_words] => 14255
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 86
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17927337
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/927337 | Methods and compositions to spread protein cargoes across multi-nucleated cells | May 20, 2021 | Issued |
Array
(
[id] => 20826571
[patent_doc_number] => 12680128
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-07-14
[patent_title] => Compositions and methods for DNA cytosine carboxymethylation
[patent_app_type] => utility
[patent_app_number] => 17/999260
[patent_app_country] => US
[patent_app_date] => 2021-05-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 30
[patent_figures_cnt] => 39
[patent_no_of_words] => 13841
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 100
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17999260
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/999260 | Compositions and methods for DNA cytosine carboxymethylation | May 18, 2021 | Issued |
Array
(
[id] => 18666507
[patent_doc_number] => 11773385
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-03
[patent_title] => High-affinity human ACE2 construct for use in diagnosing and treating coronaviruses
[patent_app_type] => utility
[patent_app_number] => 17/324585
[patent_app_country] => US
[patent_app_date] => 2021-05-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 32
[patent_figures_cnt] => 40
[patent_no_of_words] => 13411
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17324585
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/324585 | High-affinity human ACE2 construct for use in diagnosing and treating coronaviruses | May 18, 2021 | Issued |